LIQUIDIA CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
LIQUIDIA CORPORATION (LQDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $5.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-05
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $5.89M, a 12.98% decline from fiscal 2024.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $6.77M, a 33.22% decline from fiscal 2023.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $10.14M, a 129.12% increase from fiscal 2022.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $4.43M, a 28.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2025-12-31 | $5.89M 10-K · filed 2026-03-05 |
| 2024-12-31 | $6.77M 10-K · filed 2026-03-05 |
| 2023-12-31 | $10.14M 10-K · filed 2026-03-05 |
| 2022-12-31 | $4.43M 10-K · filed 2024-03-13 |
| 2021-12-31 | $6.17M 10-K · filed 2023-03-20 |
| 2020-12-31 | $4.18M 10-K · filed 2022-03-17 |
| 2019-12-31 | $4.13M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |